Comparative Genomics Analysis of Cryptosporidium Parvum and Repurposing of Triazole Derivative as Anti-Cryptosporidial Agents
Kalpana1, R.K Srivastava2, Ravindra Nath31Department of Biotechnology, Dr. Ambedkar Institute of Technology for Handicapped, Kanpur, India
2Rural Division Extension, Central Institute for Medicinal and Aromatic Plant, Lucknow, India
3University Institute of Engineering and Technology, CSJM University,Kanpur,India
Corresponding Author E-mail : kalpna@aith.ac.in
Abstract: Cryptosporidium, a member of phylum apicomplexa is considered as an opportunistic pathogen for humans as well as other important livestock. It is a causative agent for water-borne infectious diarrheal like disease cryptosporidiosis with a comparatively high mortality rate among children and immunocompromised patients worldwide. The statics shows that cryptosporidiosis is among the top three threats for the survival of infants, especially in developing countries. To date, no fully effective drug therapy is available to treat cryptosporidiosis. Therefore, the discovery and development of an effective anti-cryptosporidial drug with a novel mechanism of action have become an insistent task for controlling cryptosporidiosis. The literature revealed that various heterocyclic aromatic compounds have various invincible biological properties such as anti-fungal, anti-bacterial and anti-parasitic. Among these, Triazole is one of the most promising candidates that grab attention by researchers, chemists, microbiologists, and pharmacologists through various success stories. Triazole nucleus is present in various natural anti-infective and medicinal compounds. In this research, we have collected triazole compounds from various published works and create a database of these novel compounds for further exploration as anti-cryptosporidial compounds. It is hoped that this research provides new insights for rational anti-cryptosporidial chemotherapeutic agents who will be more active and less toxic.
Keywords: Cryptosporidiosis; IMPDH; Molecular Docking; Triazole; Virtual Screening Back to TOC